Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by BottomBrokeron Aug 07, 2024 2:37pm
129 Views
Post# 36167976

RE:RE:ProMIS Neurosciences faces Nasdaq delisting risk

RE:RE:ProMIS Neurosciences faces Nasdaq delisting riskHere it is. 

https://www.investing.com/news/company-news/promis-neurosciences-regains-nasdaq-compliance-93CH-3542094

"ProMIS Neurosciences Inc., a pharmaceutical company, announced today that it has regained compliance with the NASDAQ's minimum value requirement for continued listing on the NASDAQ Capital Market. This development follows a period of non-compliance with the NASDAQ Listing Rule 5550(b)(2), which necessitates a minimum market value of listed securities of $35 million.

The notification of compliance was received by ProMIS Neurosciences on Monday, July 22, 2024, as indicated by the company's recent 8-K filing with the U.S. Securities and Exchange Commission. The compliance was achieved after the company's common shares maintained a closing market value of $35 million or greater for at least 10 consecutive business days, from July 8, 2024, to July 19, 2024.

The company's interim Chief Executive Officer, Neil Warma, signed the SEC filing, marking the official confirmation of the regained status. The NASDAQ Capital Market is a key platform for companies like ProMIS Neurosciences, providing access to a broad set of investors and the potential for increased liquidity.

This announcement marks the end of the compliance issue, with the NASDAQ Stock Market Listing Qualifications Staff considering the matter closed. ProMIS Neurosciences, headquartered in Toronto, Canada, is listed under the ticker symbol NASDAQ:PMN and is classified within the pharmaceutical preparations industry."

<< Previous
Bullboard Posts
Next >>